These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
590 related articles for article (PubMed ID: 27372190)
1. The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention: The ADAPT-DES Study. Brener SJ; Kirtane AJ; Stuckey TD; Witzenbichler B; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Mehran R; Parvataneni R; Brodie BR; Stone GW JACC Cardiovasc Interv; 2016 Jul; 9(14):1450-7. PubMed ID: 27372190 [TBL] [Abstract][Full Text] [Related]
2. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677 [TBL] [Abstract][Full Text] [Related]
3. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963 [TBL] [Abstract][Full Text] [Related]
4. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study. Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW; JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034 [TBL] [Abstract][Full Text] [Related]
5. Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents). Kirtane AJ; Parikh PB; Stuckey TD; Xu K; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Parvataneni R; Maehara A; Généreux P; Mehran R; Stone GW JACC Cardiovasc Interv; 2015 Dec; 8(15):1978-1987. PubMed ID: 26738669 [TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961 [TBL] [Abstract][Full Text] [Related]
7. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629 [TBL] [Abstract][Full Text] [Related]
8. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study. Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F; Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531 [TBL] [Abstract][Full Text] [Related]
9. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840 [TBL] [Abstract][Full Text] [Related]
10. Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial. Legrand V; Cuisset T; Chenu P; Vrolix M; Martinez C; Dens J; Gach O; Boland J; Claeys MJ; Magne J; Barbato E; Wijns W EuroIntervention; 2014 Jun; 10(2):204-11. PubMed ID: 24952058 [TBL] [Abstract][Full Text] [Related]
11. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis). Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB; JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540 [TBL] [Abstract][Full Text] [Related]
12. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860 [TBL] [Abstract][Full Text] [Related]
13. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. Baber U; Dangas G; Chandrasekhar J; Sartori S; Steg PG; Cohen DJ; Giustino G; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Weisz G; Colombo A; Pocock S; Mehran R JACC Cardiovasc Interv; 2016 Jul; 9(13):1349-57. PubMed ID: 27388822 [TBL] [Abstract][Full Text] [Related]
14. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L; JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118 [TBL] [Abstract][Full Text] [Related]
15. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G; JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420 [TBL] [Abstract][Full Text] [Related]
16. Incidence, nature, and temporal trends of adverse events associated with noncardiac procedures among veterans with drug-eluting coronary artery stents. Salters C; Bradley B; Charnigo RJ; Shah Z; Meehan J; Abdel-Latif A; Ziada KM Catheter Cardiovasc Interv; 2015 Aug; 86(2):211-9. PubMed ID: 25323046 [TBL] [Abstract][Full Text] [Related]
17. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698 [TBL] [Abstract][Full Text] [Related]
18. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H; JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838 [TBL] [Abstract][Full Text] [Related]
19. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Stefanescu Schmidt AC; Kereiakes DJ; Cutlip DE; Yeh RW; D'Agostino RB; Massaro JM; Hsieh WH; Mauri L; Circulation; 2017 May; 135(18):1720-1732. PubMed ID: 28228427 [TBL] [Abstract][Full Text] [Related]
20. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]